+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neuroprotection - Methods, Drugs, Markets and Companies

  • ID: 4748149
  • Report
  • May 2020
  • Region: Global
  • 835 Pages
  • Jain PharmaBiotech
1 of 2

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.

Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.

The report contains profiles of 141 companies that have a neuroprotective product or products along with 126 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 1,100 references are included. Clinical trials of various neuroprotective agents are described and failures of trials are analyzed with suggestions for improving the selection of drugs and design of trials. The report is supplemented with 84 tables and 27 figures.

Market analysis of currently used products that have a neuroprotective effect are analyzed for the year 2019. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and the takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2024 when it will constitute a major and important component of the CNS market. Forecasts are made until 2029. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.

The report contains information on the following:

  • Neuroprotective Agents
  • Neuroprotection in Cerebrovascular Disease
  • Neuroprotection in Traumatic Brain Injury
  • Neuroprotection in Spinal Cord Injury
  • Neuroprotection for Neurodegenerative Disorders
  • Neuroprotection in Parkinson Disease
  • Neuroprotection in Alzheimer Disease
  • Neuroprotection in Huntington Disease
  • Neuroprotection in Amyotrophic Lateral Sclerosis
  • Neuroprotection in Miscellaneous Neurological Disorders
  • Neuroprotection in Disorders of the Optic nerve and the Retina
  • Neuroprotection during Anesthesia and Surgery
  • Markets for Neuroprotective Therapy
  • Companies Involved in Developing Neuroprotective Therapies
Note: Product cover images may vary from those shown
2 of 2

Part I: Methods & Drugs

0. Executive Summary

1. Introduction
Historical development of neuroprotection
Neurophysiological basis of neuroprotection
Astrocytic glycogen-derived lactate as fuel for the brain
Gene expression in the human brain
Role of astrocytes in neuroprotection
Role of glymphatic system in neuroprotection
Role of sleep in neuroprotection
Role of cerebral metabolism in neuroprotection
Role of circadian genes in neuroprotection
Role of blood-brain barrier in neuroprotection
Role of the gut microbiota in development of integrity of the BBB
Intrinsic neuroprotective factors
Neuroprotective gene expression
Upregulation of GADD34
Induction of NR4A proteins by CREB in neurons
Elevation PGC-1α for neuroprotection in PD
Neurotrophic factors
Intrinsic nonenzymatic antioxidants
Activation of transcription factor Nrf2
Intrinsic neuroprotective factors
Docosahexaenoic acid
Excitatory amino acid transporters
Extracellular serine protease thrombin
Heat-shock proteins
Nuclear factor I-A
Prion protein
Rai adaptor protein
Stem cell factor
Role of the immune system in neuroprotection
Induction of DNA repair enzymes for neuroprotection
Microtubule-based neuroprotective response to axonal injury
Pathomechanisms of CNS injury as basis for neuroprotection
Biomarkers of neurological disorders and neuroprotection
CNS biomarker identification using proteomics
Brain imaging for detection of biomarkers
Neuroprotection in cerebral hypoxia
Effects of hypoxia on the brain
Cerebral Metabolism During Hypoxia
Adaptive mechanisms in hypoxia
Neuroprotection in hypoxia-ischemia
Neuroprotection in neuroinflammation
Biomarkers of neuroinflammation
Neuroprotection in mental stress
Neuroprotection in disruption of circadian rhythms
Role of neuroprotection in various neurological disorders
Neuroprotection and neuroregeneration
Acute versus chronic neuroprotection
Discovery and evaluation of neuroprotective agents
Neuroprotective drug discovery
Discovery of CNS drugs that penetrate the blood-brain barrier
In vitro assays for the evaluation of neuroprotective agents
Oxidative injury model to test neuroprotective drugs
Apoptosis model for designing neuroprotective drugs
Transgenic mouse models of neurological disorders
Evaluating effects of neuroprotective drugs on living brain slices
Role of brain imaging in neuroprotective drug discovery and development
Positron emission tomography
Role of single photon emission computed tomography
Functional CT scanning to evaluate cerebrovascular protection
Magnetic resonance imaging for the evaluation of neuroprotectives
Application of nanotechnology to neuroprotection
Anthocyanin-loaded PEG-gold nanoparticles
Buckminsterfullerene C60 derivatives
Cadmium telluride nanoparticles prevent Aβ fibril formation
Ceria nanoparticles as antioxidants
Chitosan nanoparticles against oxidative stress
Nanoparticles as carriers of neuroprotective agents into the brain
Polymer nanoparticles
Squalenoyl adenosine nanoparticles
Evaluation criteria for potential neuroprotective agents

2. Neuroprotective Agents
Classification of neuroprotective agents
α2 adrenoreceptor agonists
Activated protein C
Activity-dependent neuroprotective protein
Adenosine analogs
Antidepressant-induced neurogenesis
Neurogenesis induced by electroconvulsive therapy
Neuroprotective effect of selective serotonin reuptake inhibitors
Fluoxetine as a neuroprotective agent
Antiepileptic drugs as neuroprotectives
Valproic acid
Anti-neuroinflammatory agents
Interleukin-1 antagonists
COX-2 inhibitors
Gold microparticles as anti-neuroinflammatory agents
Matrix metalloproteinase inhibitors as anti-neuroinflammatory agents
Prostaglandin receptor antagonists
Anti-apoptosis agents
Activated protein C
Calpain inhibitors
Caspase inhibitors
DNA binding drugs
Omega-3 fatty acids
Docosahexaenoic acid
Poly(ADP-ribose) polymerase inhibitors
Prevention of apoptosis by binding of proNGF to sortilin
Antioxidants/free radical scavengers
Free radical generation
Natural defenses against oxidative stress
Effects of oxidative damage
Oxidative damage and aging
Neuronal damage by free radicals
Oxidative damage and neurodegenerative disorders
Measures to control oxidative stress
Categories of therapeutic antioxidants
Coenzyme Q10
Mitochondria-targeted antioxidants
Neuroleptics as antioxidants
NRF2 for augmenting neuroprotection againt oxidative stress
Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs
Translation of antioxidant neuroprotection from preclinical to clinical
Carbon monoxide and heme oxygenase
Cell transplants
Cells secreting neuroprotective substances
Stem cells
Stem cell activation for neuroprotection/regeneration by glucocorticoids
Use of neural stem cells to construct the blood brain barrier
Non-erythropoietic EPO variants and mimics
Granulocyte colony-stimulating factor
Delta-opioid receptor agonists
Delta opioid peptide-induced hibernation for neuroprotection
Gene therapy
Glucagon-like peptide
Glatiramer acetate
Glutamate antagonists
Neuroprotection by scavenging blood glutamate
Glutamate transporters
Glutamate transporter-mediated neuroprotective effect of drugs
Neuroprotection by targeting KAI subunit of kainate receptor
Glycine-proline-glutamate analogs
Hydrogen sulfide
Hibernation induced by hydrogen sulfide
NMDA receptor ion channel complex
NMDA receptor antagonists
NMDA NR2B subunit receptor antagonists
Memantine as a neuroprotective agent
NAALADase inhibitors
AMPA receptor modulators
Metabotropic glutamate receptor modulators
Heat shock proteins
Histone deacetylase inhibitors for neuroprotection
Estrogen and neuroprotection
Neuroprotective effect of estrogen receptor ligands
Selective estrogen receptor modulators
Mitochondrial mechanisms of estrogen neuroprotection
Ion Channel modulators
Calcium channel blockers.
Na+channel blockers.
Neuroprotective potassium channel inhibitors
Kynurenine inhibitors
Leukocyte adhesion inhibitors
Neurite outgrowth-promoting agents
Monoclonal antibodies
Neurotrophic factors
Activity-dependent neurotrophic factor
Bone morphogenetic proteins
Brain-derived neurotrophic factor
Ciliary neurotrophic factor
Fibroblast growth factors
Glial cell line-derived neurotrophic factor
Insulin-like growth factor
Nerve growth factor
Osteogenic protein-1
Pigment epithelium-derived factor
Transforming growth factor-1
Vascular endothelial growth factor
Neurotrophic factor-related neuroprotective agents
Amitriptyline as a TrkA and TrkB receptor agonist
Gambogic amide
Oxygen-regulated protein 150 kD
Small molecule activators of the Trk receptors
Nicotine and nicotinic receptor agonists
Neuroprotective effect of galantamine mediated via α7nAChRs
Galantamine-induced Aβ clearance via α7nAChRs
Nitric oxide-based neuroprotection
Nitric oxide synthase inhibitors
Nitric oxide mimetics
Nitric oxide donating derivatives
Nutraceuticals and naturally-derived compounds
Mechanism of neuroprotective effect of curcumin
Green tea
Herbal preparations
Flavonoid wogonin
Punicalagin from pomegranate
Osmotic diuretics
Oxygen therapeutics
Oxygen carriers
Hemoglobin-based oxygen carriers
Perfluorocarbons as oxygen carriers
Hyperbaric oxygen therapy
P7C3 compounds
C3-derived peptide for neuroprotection and neuroregeneration
Corticotropin-releasing hormone
Thyrotropin-releasing hormone
Vasoactive intestinal peptide
Pharmacological preconditioning
PPARs as drug targets for neuroprotection
Amyloid precursor protein
Protein kinase C activators
PSD-5 antagonists
Role of RNA interference in neuroprotection
Role of miRNA in neuroprotection
Sigma receptor agonists as neuroprotective agents
SIRT group of proteins
Tauroursodeoxycholic acid
Tetanus toxin as a neuroprotective agent
Thrombolytic agents as neuroprotective agents
Uncoupling protein 2
Vaccines as neuroprotectives
Vitamins as neuroprotective agents
Vitamin B12
Vitamin D
Unconventional biologicals
Non-pharmacological approaches to neuroprotection
Caloric restriction
Cerebral exercise
Bilingualism for prevention of decline of mental function
Electrical fields for improvement of cerebral function in neurodegeneration
Environmental enrichment
Limitations of hypothermia
Hypothermic neuroprotection in hypoxia-ischemia
Ketogenic diet
Mediterranean diet
Nonpharmacological preconditioning for neuroprotection
Physical exercise
Suspended animation and neuroprotection
Transcranial magnetic stimulation

3. Neuroprotection in Cerebrovascular Disease
Pathophysiology of cerebral ischemia
Calcium overload
Cerebral edema in stroke
Cytokines and adhesion molecules in stroke
Adhesion molecules
Interleukin-1 and IL-6
Tumor necrosis factor-α
DNA damage and repair in cerebral ischemia
Gene expression in response to cerebral ischemia
Glutamate as a biomarker of stroke
Heat shock proteins in stroke
Ion channel dysfunction in stroke
Neuroinflammation in cerebral infarction
Neurotrophic factors in stroke
Problems requiring investigation of the role of NTFs in stroke
Nitric oxide in cerebral ischemia
Oxygen free radicals in cerebral ischemia
Poly(ADP-ribose) polymerase (PARP) gene
Protease-activated receptor 1
Effect on the brain of cessation of cerebral circulation
Reperfusion injury after cerebral ischemia
Neuroprotection according to zones in cerebral infarction
Zone of ischemic infarction
Current management of stroke
Neuroprotection in stenosis of intracranial arteries
Neuroprotection in stroke with intracerebral hemorrhage
Neuroprotection in cerebrovascular malformations
Arteriovenous malformations
Cavernous cerebrovascular malformations
Neuroprotective strategies for ischemic stroke in patients with dementia
Neuroprotection in transient ischemic attacks
Secondary prevention of stroke
Neuroprotective therapies for stroke
Neuroprotective strategies according to pathomechanism of stroke
Pharmacologic neuroprotective agents for stroke
αB-crystallin as a neuroprotectant in stroke
Acid-sensing ion channel blockers
Adrenergic receptor antagonists
AMPA receptor antagonists as neuroprotectives for stroke
Anesthetic agents as neuroprotectives in stroke
Propofol as neuroprotective in stroke
Antiapoptotic neuroprotectives
Creatine as neuroprotective in stroke
Lithium as a neuroprotective in stroke
TUDCA as a neuroprotective in stroke
Antidepressants as neuroprotectives agents in stroke
Fluoxetine as neuroprotectectant in stroke
Antiepileptic drugs as neuroprotectives in stroke
Anti-HMGB1 monoclonal antibody
Antiinflammatory agents
Cox-2 inhibitors for ischemic stroke
Minocycline for neuroprotection in stroke
Antioxidant approaches
Carnosine as a neuroprotective in stroke
Dehydroascorbic acid
Uric acid
Arimoclomol for stroke
Cardiac glycosides as neuroprotectives in stroke
Coagulation inhibitors as neuroprotectives
Heparin and enoxaparin
Warfarin vs dabigatran
Curcumin as a neuroprotectant in stroke
Docosahexaenoic acid for ischemic stroke
Ephrin-A5 blockers
Estrogen for stroke
Flavones for neuroprotection in stroke
Glutamate clearance from blood
Hamartin induction by cerebral ischemia as a basis for neuroprotection
Histone deacetylase inhibitors for neuroprotection in stroke
Histamine H2-receptor modulation
Inosine for stroke
Insulin-like growth factor-I
Intravenous immunoglobulin as neuroprotective in stroke
Ischemic preconditioning for neuroprotection in stroke
Ketone bodies for neuroprotection in stroke
Mineralocorticoid receptor blockade for neuroprotection
miR-223 and neuroprotection in stroke
NA-1 as neuroprotective against ischemic stroke
Nasal delivery of neuroprotective agents in stroke
Neuroserpin as a neuroprotective in stroke
N-2-mercaptopropionyl glycine
Neurotrophic factors as neuroprotectives for stroke
Brain-derived neurotrophic factor
Cerebral dopamine neurotrophic factor
Fibroblast growth factor
Granulocyte colony stimulating factor
Granulocyte-macrophage colony-stimulating factor
Glial cell line-derived neurotrophic factor
Insulin-like growth factor-1
VEGFD delivered intranasally
NO-based strategies for neuroprotection in cerebral ischemia
NOX-4 inhibitors for neuroprotection in stroke
Omega-3 fatty acids for neuroprotection after cerebral ischemia-hypoxia
Pannexin channel blockers for neuroprotection in stroke
Perlecan domain V
Peroxisome proliferator-activated receptor- agonists
Pioglitazone for reduction of stroke risk
PGE2 EP2 receptor activation
Proteoglycan-degrading enzymes
Proteosome inhibitors
Statins for prevention and neuroprotection in stroke
Stroke vaccine
Thrombosis inhibitors
Tissue plasminogen activator as neurorestorative in cstroke
Vitamin E for neuroprotection in stroke
Neuroprotection in ischemia-reperfusion injury
Methylene blue for neuroprotection in ischemia-reperfusion injury
Miscellaneous agents for neuroprotection in reperfusion injury
Neuroprotection by treatment of cerebrovascular malformations
Arteriovenous malformations
Cerebral cavernous malformations
Prevention of hemorrhage following ischemic stroke
Non-pharmacological neuroprotective therapies for stroke
Hypothermia for neuroprotection in acute stroke
Hyperbaric oxygen therapy for neuroprotection in acute stroke
Hypothermia combination with other neuroprotective strategies
Infrared laser therapy for ischemic stroke
Preconditioning for neuroprotection against cerebral ischemia
Neuroprotection in ischemia/reperfusion injury
Neurosurgical procedures for stroke
Neurosurgical procedures for neuroprotection in acute stroke
Decompressive hemicraniectomy
Multiple endovascular modalities
Neurosurgical procedures for chronic cerebral ischemia
Neurostimulation of sphenopalatine ganglion
Stent versus surgery for asymptomatic carotid stenosis
Neurorehabilitation in relation to neuroprotection in stroke
Protective effect of physical activity on stroke in the elderly
Biological therapies for stroke
Cell therapy for stroke
Stem cell transplant for stroke
Preconditioning with hyperbaric oxygen for stem cell therapy
Immortalized cell grafts for stroke
Stimulation of instrinsic stem cells for repair of brain in stroke
Gene therapy for neuroprotection in cerebrovascular disease
Regulation of microRNAs for neuroprotection in cerebral ischemia
RNAi-based therapy for neuroprotection in stroke
Vaccines for neuroprotection in stroke
Neuroprotective therapies for cerebral ischemia: clinical trials
Free radical scavengers
Failed clinical trials of neuroprotection in stroke
Erythropoietin as a neuroprotective in stroke
Causes of failure of stroke trials
Measures for prevention of failures in stroke trials
Design of acute stroke trial to facilitate drug approval
The ideal neuroprotective agent for stroke
Prevention of stroke
Concluding remarks and future of neuroprotection in stroke

4. Neuroprotection in Traumatic Brain Injury
Cerebral hypoxia/ischemia as a complication of trauma
Epidemiology of TBI
TBI in the military
Pathophysiology of TBI
Immediate damage following TBI
Blast injury sequelae
Cerebral edema following TBI
Neurometabolic cascade after TBI
Delayed damage following TBI
Mechanism of axonal damage after TBI
Role of neuroinflammation in TBI
BBB damage after TBI
Molecular events following TBI
Chronic traumatic encephalopathy
Neurocognitive sequelae of TBI
Changes in neurotrophic factors following TBI
Changes in neurotransmitters following TBI
Proteomics of TBI
Genetic influences on outcome following TBI
Management of TBI
Mana7gement during acute phase of head injury
Control of intracranial pressure and cerebral edema
Decompressive craniectomy
Neuroprotection in TBI
β- and γ-secretase inhibitors
Beta blockers
Bradykinin B2 antagonists
Cell cycle inhibitors for TBI
COX-2 inhibitors for neuroprotection in TBI
Cyclosporin for neuroprotection in TBI
Dexanabinol for TBI
Erythropoietin for neuroprotection in TBI
Gold implants for neuroprotection in focal TBI
Histone deacetylase inhibitors for neuroprotection in TBI
Inhibitors of integrated stress response
Magnesium sulfate
Minocycline for TBI
Multipotential neuroprotective agents for TBI
Neurotrophic factors for TBI
Neurosteroids as neuroprotective agents for TBI
NMDA receptor antagonists
Neuroprotection in TBI against glutamate-induced excitotoxicity
Nogo-A inhibitor
Nutritional approaches to neuroprotection in TBI
Branched chain amino acids to ameliorate cognitive impairment in TBI
Creatine for neuroprotection in TBI
Nicotinamide for neuroprotection in TBI
Omega 3 fatty acids as neuroprotectives in TBI
Oxygen carriers for TBI
Polyethylene glycol for neuroprotection in TBI
Propofol for neuroprotection in TBI
Rapamycin as neuroprotective in TBI
Simvastatin as neuroprotective in TBI
Statins as neuroprotective agents in concussion
Targeting mitochondrial pathology in TBI
Thyrotropin-releasing hormone analogs
Tissue plasminogen activator
Biological approaches to neuroprotection in TBI
Antisense approaches to TBI
Cell therapy for TBI
Limitations of stem cell therapy for acute TBI
Stem cell-derived exosomes for treatment of TBI
Gene therapy for TBI
Vaccines for TBI
Non-pharmaceutical approaches to neuroprotection in TBI
Deep brain stimulation for TBI
Hyperbaric oxygen therapy for TBI
Reduction of microglial migration after TBI
Vacuum for mechanical tissue resuscitation in TBI
Prophylactic neuroprotection against TBI
Role of helmets in protection against TBI
Role of physical exercise in protection against TBI
Neuroprotection against late sequelae of TBI
Antiepileptic drugs for prevention of seizures and neuroprotection
Neuroprotection during rehabilitation phase of TBI
Neuroregeneration following TBI
Intrinsic factors that influence regeneration following TBI
Causes of lack of regeneration following TBI
Approaches to regeneration of the brain following TBI
Clinical trials of neuroprotective agents in TBI
Ongoing clinical trials in TBI
Failed clinical trials in TBI
Differences between clinical trials and studies in animal models of TBI
Subgroup analysis
Improving the clinical trial design
Clinical trials combining multiple treatment strategies
Shortening the trial time
Conclusions and future of neuroprotection in TBI

5. Neuroprotection in Spinal Cord Injury
Pathophysiology of SCI
Secondary mechanisms of SCI
Neurotrophic factor changes in SCI
Management of SCI
Pharmacological neuroprotective agents for SCI
Antibodies as neurite growth inhibitors in SCI
Antiexcitotoxic agents
GM-1 ganglioside
Bacterial enzyme chondroitinase ABC
Docosahexaenoic acid as neuroprotective in SCI
Erythropoietin as a neuroprotective in SCI
Free radical scavengers for neuroprotection in SCI
Immunosuppressants as neuroprotectants in SCI
Interleukin-10 for neuroprotection in SCI
Matrix metalloproteinase inhibitors for SCI
Minocycline as neuroprotective in SCI
Modulation of macrophage responses for neuroprotection after SCI
Neurotrophic factors for neuroprotection after SCI
Fibroblast growth factors in the management of SCI
Promotion of regeneration of neurons in SCI
Rho pathway and Rho antagonists in SCI
Riluzole and methylprednisone as neuroprotectants in SCI
Selenium as a neuroprotective for SCI
Sialidase for enhancing recovery after SCI
Targeting the inflammatory response for neuroprotection in SCI
Uric acid as neuroprotective in SCI
Non-pharmacological approaches to SCI
Hyperbaric oxygen therapy
Hypothermia for SCI
Cell therapy for SCI
Fetal neural grafts for SCI
Olfactory-ensheathing cells for SCI
Oligodendrocyte precursor cells for treatment of SCI
Schwann cell transplants for SCI
Transplantation of glial cells for SCI
Stem cells for SCI
Bone marrow stem cells for SCI
Transplantation of ESCs for SCI
Transplantation of induced pluripotent stem cells in SCI
Transplantation of MSCs for SCI
Transplantation of NSCs for SCI
Transdifferentiation of stem cells into cholinergic neurons for SCI
Gene therapy for SCI
Combined approaches to spinal cord injury
Discovery of new targets for neuroprotective therapies in SCI
Clinical trials in SCI
Concluding remarks

6. Neuroprotection in Neurodegenerative Disorders
Pathomechanism of neurodegeneration
Aging and neurodegeneration
α-synuclein in neurodegeneration and neuroprotection
Dysregulation of cyclin-dependent kinase 5
Dysregulation of translation
Exosomes in CNS neurodegeneration and neuroregeneration
Genomics of neurodegenerative diseases
Impairment of neural transport in neurodegenerative disorders
Lack of neurotrophic factors
Mitochondrial damage leading to apoptosis
Neuroinflammation in neurodegenerative disorders
Neurodegeneration associated with chronic repeated cerebral injuries
Neurodegeneration associated with protein misfolding
Modulation of neurodegeneration by molecular chaperones
Intrabodies targeting protein misfolding in neurodegeneration
Targeting proteins aggregation to prevent amyloid formation
Tau and neurodegeneration
Role of apoptosis in neurodegenerative disorders
Role of glia in neurodegeneration
Role of metals in neurodegeneration
Spread of neurodegeneration
TDP-43 proteinopathy and neurodegenerative diseases
Viral infections and neurodegeneration
AIDS and the nervous system
Avian influenza as cause of neurodegeneration
Neurodegenerative disorders with dementia
Dementia with Lewy bodies
Frontotemporal dementia
Progressive supranuclear palsy
Genetic disorders with neurodegeneration
Batten disease
Cell and gene therapies
Cerliponase alfa
Familial dysautonomia
Friedrich ataxia
Pathomechanism of FA
Neuroprotection in FA
Leigh syndrome
Niemann-Pick type C disease
Spinal and bulbar muscular atrophy
Spinal muscular atrophy
Creutzfeldt-Jakob disease
Neuroprotection in Creutzfeldt-Jakob disease
Pharmacological neuroprotectants against CJD
Innovative approaches to neuroprotection in CJD and future prospects
Approaches to neuroprotection in neurodegenerative disorders
Glutamate-based therapies for neurodegenerative disorders
Histone deacetylase inhibitors for neurodegenerative disorders
Intermittent fasting for neuroprotection
Iron chelation for neuroprotection
Mitochondria permeability transition pore complex and neuroprotection
Modulation of proteostasis in neurodegenerative disorders
Targets to limit protein aggregation in neurodegenerative diseases

7. Neuroprotection in Parkinson Disease
Epidemiology of Parkinson's disease
Pathophysiology of Parkinson's disease
Alteration of dopamine homeostasis
Calcium interaction with α-synuclein
Disruption of iron homeostasis
Genes and PD
Histone deacetylase 4 as a regulator of progression of PD
Oxidative stress
Propagation of pathologic α-synuclein from the gut to the brain in PD
Role of neurotrophic factors
Role of misfolding proteins
Role of -synuclein in dementia of PD
Synaptic vesicle glycoprotein 2C disruption in PD
Neuroprotective strategies for PD based on pathomechanism
A genetic animal model of PD for testing neuroprotective strategies
Aldehyde dehydrogenase 1 protects nigrostriatal dopaminergic neurons
RNAi screening to identify neuroprotective genes in a PD model
Strategies to stop aggregation of -synuclein
Targeting mitochondrial dysfunction in PD
Management of Parkinson's disease
Limitation of conventionally administered dopamine therapy
Neuroprotective therapy in PD
Neuroprotective effect of currently used drugs for PD
Rasagiline mesylate
Rivastigmine for treatment of dementia and falls associated with PD
Non-pharmacological strategies for neuroprotection in PD
Deep brain stimulation for PD
Effect of exercise and environmental enrichment on PD
Calorie restriction in PD
Development of neuroprotective therapies for PD
2B3-201 for targeted delivery of methylprednisolone
Adenosine AA2 receptor antagonists
Antiapoptotic strategies for PD
ATP13A2 activation
Augmenting CNS glucocerebrosidase activity
β2-Adrenoreceptor agonists
BT13 as GDNF receptor agonist
Calcium channel blockers for PD
Cell therapies for PD
Stem cells for PD
Activation of endogenous stem cells and neural precursors
Pluripotent stem cell-derived neurons
Transplantation of iPSC-derived neural progenitors
Conserved dopamine neurotrophic factor for PD
Doxycyline as a neuroprotectant in PD
Free radical scavengers for neuroprotection in Parkinson’s disease
Tea extracts as neuroprotectives
Gene therapy for PD
Implantation of genetically engineered cells
Gene therapy using GDNF
Parkin gene therapy
Viral vector-based ubiquitination to prevent spread of α-synuclein
Concluding remarks about gene therapy for PD
Heat shock protein 70
Liver X receptor β agonists
Melatonin as a neuroprotectant in PD
Nicotine as a neuroprotective in PD
Nilotinib for PD
Neuroprotective effect of leucine-rich repeat kinase-2 inhibitors
Neuroprotective effect of DJ-1 protein
Neurotrophic factors
Basic fibroblast growth factor for PD
Neurturin for PD
Platelet derived growth factor
Nrf2-mediated neuroprotection in PD
Nuclear receptor-related 1:Retinoid X receptor α activation
Omega-3 polyunsaturated fatty acids
RAB3B overexpression
Reservatrol for PD
RNAi therapy for PD
Sirtuin 2 inhibitors for neuroprotection in PD
Squalamine and PD
Statins and PD
Targeting Bax
Vitamin D for neuroprotection in PD
Vaccine for PD
Clinical trials of neuroprotection in Parkinson's disease
Evaluation of neuroprotective therapies for PD
Current status and future challenges for neuroprotection in PD

8. Neuroprotection in Alzheimer Disease
Pathomechanism of Alzheimer's disease
Pathology of AD
Cerebral atrophy and neuronal loss
Neuritic plaques and neurofibrillary tangles
Role of tau in the pathogenesis of AD
RNA-binding proteins and AD
Amyloid precursor protein
APP intracellular domain
Relation of APP mutations to CNS disorders
Relation of APP to Aβ deposits and pathogenesis of AD
Role of neprilysin in Aβ degradation
Role of secretases in amyloid cascade
Role of nicastrin
Neurotoxicity of Aβ deposits
Aβ production and clearance
Aβ-mediated synaptic and cognitive deficits
Interaction of Aβ with neuron-specific Na+/K+-ATPase α3 subunit
Relation of Aβ deposits to synaptic activity
Role of dsDNA breaks in neurodegeneration due to Aß
Sequence of events in neurotoxicity of Aβ
Impairment of mitochondrial energy metabolism
Disturbances in brain metabolism in early AD
Disturbance of lipid metabolism in the brain
Dopamine and AD
Functioning role of genes in pathomechanism of AD
Insulin, diabetes and AD
Mechanisms underlying cognitive deficits in AD
Microglia and AD
Neuroinflammation and AD
Nitric oxide and AD
Oxidative stress and AD
Spread of neurodegeneration
Risk factors in the etiology of AD
Epigenetic link between aging and AD
Level of education/type of job and risk of AD
Metals and AD
Psychosocial stress and risk of AD
Sleep deprivation
Traumatic brain injury and AD
AD and cognitive impairment with aging
Concluding remarks on pathophysiology of AD
Management of Alzheimer's disease
Neuroprotective approaches to Alzheimer's disease
Antiapoptotic agents
Antiinflammatory drugs for neuroinflammation
Nitric oxide-donating NSAIDs
PPARgamma agonists
Antioxidant and free radical scavengers
Dehydroascorbic acid
Reservatrol for AD
Antisense approaches to AD
Antisense PNA in AD
Antisense tau in AD
Cell therapy for AD
Choroid plexus epithelial cells for AD
Stem cell transplantation for AD
Autologous adipose tissue derived mesenchymal stem cells
Neural stem cells transplantation
Neuronal differentiation of implanted NSCs enhanced by drugs
NSCs improve cognition in AD via BDNF
Potential benefits of grafting NSCs in AD
Use of autologous stem cells for dementia
Clearance of Aβ deposits and plaques
Galantamine-induced Aβ clearance
Monoclonal antibodies for removal of Aβ
Nanotechnology for removal of Aβ deposits
Cholesterol lowering agents for AD
Statins for reducing the risk of AD
Gene therapy for Alzheimer disease
NGF gene therapy for AD
FGF2 gene transfer in AD
Neprilysin gene therapy
Viral gene transfer of APPsα for rescuing synaptic failure in AD
Gene vaccination
Combination of gene therapy with other treatments for AD
Glutamate antagonists
Inhibition of Aβ formation
Chelation of metals
Copper chelation
Next generation multifunctional chelating agents for AD
Secretase modulators
Neuroprotection by α-secretase cleaved APP
Inhibitors of β-secretase
Inhibitors of γ-secretase
Miscellaneous neuroprotective agents
Ginko biloba
Tetrahydrocannabinol for neuroprotection in AD
Nanobiotechnology-based therapeutics for AD
Nanobody-based drugs for AD
Nanoencapsulation for delivery of vitamin E for Alzheimer disease
Selegiline-PEG nanoparticles targeting Aβ fibrils in Alzheimer disease
Neurotrophic factors for neuroprotection in AD
Brain derived neurotrophic factor
Neotrofin (AIT-082)
Small molecule compounds binding to neurotrophin receptor p75NTR
Limitations of the use of NTFs for AD
Neuroprotective effect drugs not primarily developed for AD
Antiepiletic drugs
Antimicrobial drugs
Antimicrobial drugs against Chlamydia pneumoniae
Antiviral therapy in AD
Antidiabetic drugs
Antihypertensive drugs
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Drugs acting on estrogen receptors
Granulocyte-macrophage colony-stimulating factor
Inhibitors of neuroinflammation
Interferon beta-1a
MAO-B inhibitors
Ladostigil tartrate
Methylene blue
Phosphodiesterase inhibitors as neuroprotectives
Valproic acid
Restoration of factors deficient in the aging brain
Reversal of cognitive impairment in aging by activation of creb protein
Reversal of cognitive impairment in aging by GDF11 protein
Restoration of repressor element 1-silencing transcription factor
Vaccines for AD
Active immunization with Aβ
Passive immunization with MAbs
Other vaccines for AD
Mechanism of reduction of A plaque pathology by immunization
Perspectives on vaccines for AD
Vitamin E as antioxidant
Vitamin B for lowering homocysteine
Folic acid
Combined therapeutic approaches to AD
Clinical trials in AD
Concluding remarks on clinical trials of AD
Future prospects of neuroprotection in AD
Mild cognitive impairment
Relation of MCI to AD
Neuroprotection in MCI
Pharmacological approaches for MCI
Non-pharmacological approaches to MCI and AD

9. Neuroprotection in Huntington Disease
Pathophysiology of HD
Management of Huntington's disease
Neuroprotection in Huntington's disease
Antipsychotic D2 and 5-HT1A antagonists
Caspase inhibitors
Cysteine and neuroprotection in HD
Cysteine metabolism reprogramming for neuroprotection in HD
Drugs that block inappropriate calcium release from neurons
Enhancing protease activity for clearance of mHtt
Eicosapentaenoic acid
Free radical scavengers
Histone deacetylase inhibitors
Phosphodiesterase inhibitors
Polyglutamine aggregation inhibitors
RRAS signaling pathway inhibition
Simvastatin as a neuroprotective in HD
Single chain Fv antibodies
SIRT1 activators for neuroprotection in HD
SIRT2 inhibitors for neuroprotection in HD
Synaptic activation of NMDA receptors
Targeting mutant huntingtin protein
Combinatorial therapy and targeting multiple pathways in HD
Cell therapy for HD
Cell transplants for HD
Stem cell-based therapy for HD
Neurotrophic factors and gene therapy
Antisense therapeutics for Huntington's disease
HTTRx/RG6042 for HD
RNAi-based therapies for Huntington's disease
10. Neuroprotection in Amyotrophic Lateral Sclerosis
Pathophysiology of ALS
Neuroprotective therapies for ALS
Activated protein C
Antisense therapy
Arimoclomol for ALS
Ceftriaxone for ALS
Coenzyme Q10 for ALS
COX-2 inhibitors for ALS
Diallyl trisulfide
Edaravone for ALS
Erythropoietin for ALS
Gene therapy for ALS
Gene editing for ALS
Glatiramer acetate
Insulin-like growth factor
Ketogenic diet for neuroprotection in ALS
Lithium for neuroprotection in ALS
Melatonin for ALS
Olesoxime as neuroprotective for ALS
RNAi-based therapy for ALS
Sodium phenylbutyrate
Stem cell therapy
Clinical applications
Stem cell-based drug discovery for ALS
Suppressors of mTDP-43 toxicity
Vaccination for ALS caused by SOD1 mutations
Vascular endothelial growth factor for ALS
Vitamin E for ALS
Clinical trials of neuroprotective therapies for ALS
Concluding remarks and future prospects
Multi-omics approach to ALS
Use of CRISPR/Cas9 technology to find new targets in ALS
Concluding remarks on neuroprotection in ALS

11. Neuroprotection in Miscellaneous Neurological Disorders
Neuroprotection in synaptopathies
Neuroprotection in ASD
Neuroprotection in fragile X syndrome
Neuroprotection in dementia
Age-related dementia
Aging brain and oxidative stress
Hsp70 and age-related neurodegeneration
Pharmacological approaches for treatment of age-related dementia
Mental training to prevent decline of mental function with aging
Physical exercise to prevent decline of mental function with aging
Concluding remarks on neuroprotection of the aging brain
Vascular dementia
Prediction of dementia in persons with vascular risk factors
Management of subcortical vascular dementia
Neuroprotection in Lewy body dementia
Neuroprotection in AIDS dementia
Multiple system atrophy
Mechanisms of neuronal damage in epilepsy
Strategies for neuroprotection in epilepsy
AEDs and neuroprotection
Cell therapy for neuroprotection in epilepsy
Cell therapy of posttraumatic epilepsy
Cell therapy for temporal lobe epilepsy
Cell therapy for pharmacoresistant epilepsies
Drugs targeting mossy cells in drug-resistant epilepsy
Gene therapy for neuroprotection in epilepsy
Hyaluronan-based preservation of brain ECS volume
Hypothermia for neuroprotection in status epilepticus
Ketogenic diet for prevention of seizures
miR-211 as an attenuator of cholinergic-mediated seizures
Multiple sclerosis
Epidemiology of multiple sclerosis
Current management of multiple sclerosis
Specific therapies for MS based on pathomechanism
Neuroprotection in multiple sclerosis
Clinical trials of neuroprotective therapies for MS
Neuroprotection by control of progressive forms of multiple sclerosis
Neuroprotection by controlling autoimmune inflammation in the brain
Neuroprotection by sealing the BBB with imatinib
TRPM4 cation channel blockers
Remyelination for neuroprotection in multiple sclerosis
Agents for neuroprotection in multiple sclerosis
Angiotensin-II inhibitors
Antiglutamate agents
Antioxidants for neuroprotection in MS
Antisense and RNAi approaches to MS
B cell depletion therapy
Cell therapy for multiple sclerosis
Cannabinoids for neuroprotection in MS
Curcumin as a neuroprotectant in multiple sclerosis
Cytokine-directed therapies in MS
Dalfampridine in MS
Dimethyl fumarate and diroximel fumarate
DNA vaccine for MS
Erythropoietin as a neuroprotective in MS
Fusokine composed of GM-CSF and IL-15 for immune suppression
Gene therapy for MS
Ibudilast for MS
Iron chelators
Kinase inhibitors
Melatonin for MS
Minocycline for MS
Monoclonal antibodies for MS
Natural human antibodies for repair of myelin
Neurotrophic factors for multiple sclerosis
Oral immunomodulatory agents for MS
Protein kinase Cβ as a therapeutic target for stabilizing BBB in MS
Recombinant T-cell ligands
Statins for MS
Tolerance-directed immunotherapy for MS
Ursolic acid
Concluding remarks and future prospects for neuroprotection in MS
Neuroprotection in anti-NMDA receptor encephalitis
Neuroprotection in transverse myelitis
Neuroprotection in decompression sickness
Neuroprotection in victims of drowning
Neuroprotection in CSF circulatory disorders
Neuroprotection in hydrocephalus
Neuroprotection in normal pressure hydrocephalus
Neuroprotection in infections of the CNS
Neuroprotection in bacterial meningitis
Mechanism of neural injury in bacterial meningitis
Strategies for neuroprotection
Neuroprotection in progressive multifocal leukoencephalopathy
Neuroprotection in cryptococcal meningitis
Neuroprotective approach to rabies
Neuroprotection in cerebral malaria
Neuroprotection in complications of systemic disorders
Neurological complications of cardiovascular disorders
Neuroprotection after myocardial infarction
Neuroprotection in hypertensive encephalopathy
Management of hypertension to prevent dementia
Neuroprotection in complications of diabetes
Neuroprotection in hypoglycemic coma
Neuroprotection in diabetic ketoacidosis
Neuroprotection in diabetic retinopathy
Neurological complications of liver disorders
Hepatic encephalopathy
Bilirubin encephalopathy
Neuroprotection in neurological complications of renal disease.
Neuroprotection in fever
Pharmacologic approaches for fever
Cooling the brain for neuroprotection
Neuroprotection in toxic encephalopathies
Encephalopathy due to organophosphorus poisoning
Sarin gas
Neuroprotection against chemotherapy-induced brain damage
Neuroprotection against alcohol
Alcoholic neurologic disorders
Fetal alcohol syndrome
Pathogenesis of alcohol-induced damage to the nervous system
Neuroprotection against neurotoxicity of alcohol
Neuroprotection against exposure to therapeutic radiation
Neuroprotection against radiation encephalopathy
Role of SOD in protection again radiation-induced hippocampal dysfunction
Catalase reduces mitochondrial ROS for neuroprotection from proton irradiation
Neuroprotection of the fetus and the neonate
Neuroprotection in preterm babies
Neuroprotection in neonatal hypoxic-ischemic brain injury
Pathomechanism of neonatal hypoxic-ischemic brain injury
Management of neonatal hypoxia-ischemia
Approaches to neuroprotection in neonatal hypoxia-ischemia
Hyperbaric oxygen for neonatal hypoxia-ischemia
Hypothermia for neonatal hypoxia-ischemia
Melatonin for neonatal hypoxia-ischemia
Minocycline for neonatal hypoxia-ischemia
Nicotinamide mononucleotide adenylyl transferase 1
Nitric oxide inhalation for neonatal hypoxia-ischemia
Plasminogen activator inhibitor-1 for neonatal hypoxia-ischemia
Recombinant erythropoietin for neonatal hypoxia-ischemia
Neuroprotection in carbon monoxide poisoning
Pathomechanism of CO poisoning as a basis for neuroprotection
Management of CO poisoning
Neuroprotection after cardiac arrest
Neuroprotection in delayed post-hypoxic leukoencephalopathy
Neuroprotection in sleep apnea
Neuroprotection in mitochondrial dysfunction
Mitochondrial permeability transition
Mitochondrial approaches for neuroprotection
Methylene blue
Mitochondrial encephalopathies
Neuroprotection in mitochondrial encephalopathies
Neuroprotection in psychiatric disorders
Electroconvulsive therapy and neuroprotection
Neuroprotection in schizophrenia
Cognitive impairment in schizophrenia
Neuroprotection in stress-induced neuropsychiatric disorders
Adenosine A2A receptor antagonists for neuroprotection in stress
Role of neurotrophic factors in stress-induced psychiatric disorders
Stress and dementia
Neuroprotection in hearing loss
Causes of hearing loss
Pathomechanism of hearing loss
Prevention and treatment of hearing loss
Hyperbaric oxygen for hearing loss
Stem cell therapy for sensory hearing loss
Gene therapy for sensorineural hearing loss
Pharmaceutical approaches to hearing loss
Prevention of drug-induced hearing loss
Neuroprotection of peripheral nerves
Neuroprotective agents for peripheral nerves
Acetyl-L-carnitine for peripheral nerve injuries
Atorvastatin for peripheral nerve injuries
Erythropoietin for neuroprotection in peripheral nerve injuries
Neuroprotection in peripheral nerve injuries
Role of hyperbaric oxygen in peripheral nerve injuries
Role of neurotrophic factors in peripheral nerve injuries
Pharmacological approaches to Schwann cells
Role of gene therapy in neuroprotection of injured peripheral nerves
Schwann cell transplantation for peripheral nerve injury
Targeting Wallerian degeneration slow protein for neuroprotection
Peripheral neuropathy
Neuroprotection in diabetic neuropathy
Cell therapy for neuroprotection in diabetic neuropathy
Gene therapy in diabetic neuropathy
Neuroprotection in chemotherapy-induced neuropathy
Neuroprotection in chronic inflammatory demyelinating polyradiculoneuropathy
Neuroprotection in Charcot-Marie-Tooth disease 1A

12. Neuroprotection of the Optic nerve and the Retina
Optic neuropathy
Neuroprotection in optic neuritis
Eculizumab for neuromyelitis optica
Sodium channel blockers
Neuroprotection in optic nerve trauma
Potential regeneration of the optic nerve
Neuroprotection of optic nerve in glaucoma
Aminoguanidine as a neuroprotective in glaucoma
Antiglutamate agents for neuroprotection of optic nerve
NGF eye drops
Targeting Aβ in glaucoma treatment
TNF-α blockers for neuroprotection in glaucoma
Concluding remarks about neuroprotection in glaucoma
Neuroprotection in retinal ischemia
β-adrenoceptor antagonists
Brimonidine as a neuroprotective is ischemic retinopathy
Endogenous neuroprotection in the retina
Erythropoietin for neuroprotection of retinal ischemia
Gene therapy for retinal neuroprotection
Hyperbaric oxygen for central retinal artery occlusion
Levodopa for treating non-arteritic anterior ischemic optic neuropathy
Thioredoxin as a neuroprotective agent in retinal ischemia
Protection against oxygen-induced retinopathy
Neuroprotection in macular degeneration
Pathomechanism of AMD
Current treatment of AMD
Novel neuroprotective strategies against retinal degeneration
Antiangiogenic agents
Humanized MAb against Aβ
LXR agonists
Neurotrophic factors for neuroprotection in AMD
CNTF for neuroprotection in AMD
N-acetylserotonin derivatives
Nutritional protection against AMD
Progestogenic hormones
Protection of retinal cells from oxidative-stress-induced apoptosis
Cell therapy for macular degeneration
Retinal pigment epithelial cells
Stem cell transplantation in the retina
Neural progenitor cells
hESC-derived RPE cells for AMD
Gene therapy for retinal degeneration
Combining stem cell and gene therapies for retinal disorders
RNAi-based treatments for AMD
Neuroprotection in proliferative diabetic retinopathy
RNAi-based approaches to diabetic retinopathy
Clinical trials for optic nerve and retinal neuroprotection

13. Neuroprotection during Anesthesia and Surgery
Anesthetic agents as neuroprotectives
Gaseous anesthetics
Local anesthetics
Monitoring of CNS function during anesthesia and surgery
Monitoring of cerebral function
Monitoring of spinal cord function during spinal surgery
Perioperative neuroprotection
Neuroprotection during cardiovascular procedures
CNS complications of cardiac surgery
Neuroprotective strategies during cardiac surgery
Neuroprotection before anticipated or induced cardiac arrest
Neuroprotection during coronary artery bypass grafting
Preconditioing with hyperbaric oxygen
Neuroprotection in aortic surgery
Pharmacologic strategies for neuroprotection in aortic surgery
Cerebral protection during organ transplantation surgery
Cerebral protection in neurosurgery
Cerebral angiography and endovascular surgery
Cerebral protection during surgery for arteriovenous malformations
Cerebral protection during surgery of intracranial aneurysms
Management of subarachnoid hemorrhage
Vasospasm associated with subarachnoid hemorrhage
Cerebral protection during carotid endarterectomy
Cerebral protection during surgery of brain tumors
Neuroprotective measures prior to surgery
HBO preconditioning for neuroprotection during surgery
Neuroprotection following surgery
Neuroprotection by cranioplasty after decompressive craniectomy

Table 1-1: Historical landmarks in the development of neuroprotection
Table 1-2: Intrinsic neuroprotective factors
Table 1-3: Common features of pathophysiology of brain damage in diseases
Table 1-4: Place of neuroprotection in management of CNS disorders
Table 1-5: Indications for the use of neuroprotection
Table 1-6: Neuroprotective nanoparticles
Table 2-1: A classification of neuroprotective agents
Table 2-2: The neuroprotective effect of antiepileptic drugs
Table 2-3: Neuroprotective affect of minocycline in animal models
Table 2-4: Classification of antioxidants or free radical scavengers with neuroprotective potential
Table 2-5: Role of erythropoietin in the nervous system
Table 2-6: Ionotropic glutamate receptors
Table 2-7: Classification of metabotropic glutamate receptors (mGluRs)
Table 2-8: Methods for neuroprotection based on nonpharmacological preconditioning
Table 3-1: Cerebrovascular diseases that are relevant to neuroprotection
Table 3-2: Neuroprotective strategies for stroke
Table 3-3: Selected effective combinations of hypothermia with other neuroprotective strategies for the treatment of ischemic stroke in experimental models
Table 3-4: Neuroprotective gene transfer in models of cerebral ischemia
Table 3-5: Neuroprotective gene therapy in animal stroke models
Table 3-6: Neuroprotective agents in clinical development for acute cerebrovascular disease
Table 3-7: Some failed trials for neuroprotective therapy for stroke
Table 3-8: Preclinical assessment of neuroprotective agents in acute stroke models
Table 3-9: Stroke prevention based on control of risk factors
Table 4-1: Classification of closed TBI
Table 4-2: Pathophysiologic responses to TBI and for neuroprotective strategies
Table 4-3: Current conventional management of traumatic brain injury
Table 4-4: Neuroprotective strategies for traumatic brain injury
Table 4-5: Intrinsic factors that influence regeneration in the central nervous system
Table 4-6: A classification of approaches to regeneration of the brain following injury
Table 4-7: Ongoing or completed clinical trials for neuroprotection in TBI
Table 4-8: Discontinued or failed clinical trials for neuroprotection in TBI
Table 5-1: Secondary mechanisms in spinal cord injury
Table 5-2: Neuroprotective and regenerative approaches for SCI
Table 5-3: Clinical trials for neuroprotection in SCI
Table 6-1: Neurodegenerative disorders with dementia
Table 6-2: Drugs in clinical trials for spinal muscular atrophy
Table 6-3: Pharmacological approaches to neuroprotection in CJD
Table 6-4: Glutamate-based therapies in clinical development for neurodegenerative disorders
Table 7-1: Prevalence of Parkinson's disease in major markets 2019-2029
Table 7-2: Factors in the etiology of Parkinson's disease
Table 7-3: Strategies for the treatment of Parkinson's disease
Table 7-4: Gene therapy techniques applicable to Parkinson disease
Table 7-5: Current clinical trials of neuroprotective therapies for Parkinson disease
Table 7-6: Failed clinical trials of neuroprotective therapies for Parkinson disease
Table 7-7: Evaluation of neuroprotective agents for PD
Table 8-1: Relation of mutations in amyloid precursor protein to CNS disorders
Table 8-2: Risk factors for Alzheimer's disease
Table 8-3: Cholinergic approaches to the treatment of Alzheimer's disease
Table 8-4: Neuroprotective approaches to Alzheimer's disease
Table 8-5: Clinical trials in Alzheimer disease
Table 8-6: Discontinued, failed or inconclusive clinical trials of Alzheimer disease
Table 8-7: Strategies for discovery of neuroprotective therapies for AD
Table 9-1: Neuroprotective approaches in HD
Table 10-1: Hypotheses for the pathogenesis of amyotrophic lateral sclerosis
Table 10-2: Genetic diagnostic biomarkers of ALS
Table 10-3: Classification of neuroprotective agents for amyotrophic lateral sclerosis
Table 11-1: Therapeutic approaches to subcortical vascular dementia
Table 11-2: Measures for neuroprotection against the sequelae of seizures
Table 11-3: Neuroprotective effect of AEDs in animal models of status epilepticus (SE)
Table 11-4: Specific therapies for MS based on postulated pathomechanisms
Table 11-5: Approved neuroprotective therapies for multiple sclerosis
Table 11-6: Neuroprotective therapies for multiple sclerosis in clinical trials
Table 11-7: Measures to prevent acute bilirubin encephalopathy
Table 11-8: Fever associated with neurologic disorders
Table 11-9: Approaches to neuroprotection in neonatal hypoxia-ischemia
Table 11-10: Drugs with neuroprotective effect at mitochondrial level
Table 11-11: Causes of sensorineural hearing impairment
Table 11-12: Strategies for prevention and treatment of sensorineural hearing loss
Table 11-13: Agents for neuroprotection of the peripheral nervous system
Table 11-14: Neuroprotective agents for chemotherapy-induced peripheral neuropathy
Table 12-1: Causes of optic neuropathy
Table 12-2: Clinical trials of neuroprotective therapies in optic neuritis
Table 12-4: Strategies for neuroprotection in retinal ischemia
Table 12-5: Novel neuroprotective strategies against retinal degeneration
Table 12-6: Clinical trials for retinal neuroprotection
Table 13-1: CNS complications associated with cardiac procedures
Table 13-2: Strategies for protection of the brain during cardiac surgery
Table 13-3: Medical and surgical methods of cerebral vasospasm management
Table 13-4: Neuroprotection by prevention of vasospasm

Figure 1-1: A three-stage model of ischemic hypoxic disturbances of the brain
Figure 2-1: Mechanism of neuroprotective effect of sigma-1 receptor agonists
Figure 2-2: NMDA receptor ion channel complex
Figure 2-3: Neuroprotective effect of galantamine
Figure 3-1: Some steps in the ischemic cascade and site of action of neuroprotectives
Figure 3-2: Relationship between dementia and acute ischemic stroke
Figure 3-3: Pathomechanism of ischemic stroke and neuroprotective strategies
Figure 3-4: Molecules involved in preconditioning for neuroprotection in ischemia
Figure 3-5: A roadmap for neuroprotection
Figure 4-1: Cascade of events following traumatic brain injury
Figure 4-2: Neurometabolic cascade of mild TBI
Figure 4-3: Secondary injury mechanisms after TBI
Figure 4-4: Management of raised ICP after TBI
Figure 5-1: Pathomechanism of acute spinal cord injury
Figure 6-1: Identification of protein targets in neurodegenerative disorders
Figure 7-1: Neuroprotective strategies against death of dopamine-containing neurons in PD
Figure 8-1: Mechanisms of Aβ clearance
Figure 8-2: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease
Figure 8-3: Oxidative stress and Alzheimer disease
Figure 8-4: Pathomechanism of AD
Figure 9-1: Role of HTT protein in pathogenesis of HD and points of intervention
Figure 11-1: A schematic overview of synaptopathies
Figure 11-2: Common mechanisms of neural damage in cerebral ischemia and seizures
Figure 11-3: Role of neuroprotection in epilepsy and its treatment
Figure 11-4: Mechanisms of neonatal hypoxia-ischemia and targets for neuroprotection

Part II: Markets & Companies

14. Markets for Neuroprotective Therapies
The financial burden of CNS damage
Markets for neuroprotective therapies
Markets according to therapeutic areas
CNS injury
Alzheimer disease
Parkinson disease
Multiple sclerosis
Values of neuroprotective therapies in major world markets
Unmet needs in neuroprotectives
Future of neuroprotective therapies
Challenges in neuroprotective drug development
Promising areas of research in neuroprotection
Autoreactive antibodies
Biological therapies for neuroprotection
Multidisciplinary approaches to neuroprotection

15. Companies Developing Neuroprotective Therapies
Profiles of companies

16. References

Table 14-1: Neuroprotective market values 2019-2029
Table 14-2: Values of neuroprotective therapies in major world markets from 2019-29
Table 15-1:Pipeline of Alkahest
Table 15-2: Collaborations of companies in the area of neuroprotection

Figure 14-1: Unmet therapeutic needs in neuroprotective therapies
Figure 15-1: Neurovive’s pipeline

Note: Product cover images may vary from those shown
3 of 2